Katherine Panageas, DrPH

Associate Attending Biostatistician

Share
Print
Share
Print
Katherine Panageas, DrPH

Office Phone

646-888-8237

Education

Columbia University

Current Research Interests

Dr. Panageas is involved in the analysis of cluster correlated data and random effects models in the context of health services research. She is currently involved in developing a framework for hospital profiling in cancer care in collaboration with colleagues from the Center for Health Policy and Outcomes. Profiling hospitals and/or physicians based on the quality of care they provide to patients is a priority for policy makers, payers, and the public. Her future research in this area involves evaluating risk-standardized outcomes as performance metrics after major cancer surgery across all US hospitals. The goal is to recommend a practical and technically sound statistical approach that is credible and transparent to identify providers as good or poor performers in relation to benchmarks of performance. Dr. Panageas primarily collaborates with clinical investigators from the Melanoma Service and the Departments of Neurology and Neurosurgery to design and analyze prospective and retrospective studies to evaluate treatment strategies including immuno-therapies, explore various biomarkers, develop prediction models and develop models to estimate the risk of developing distant metastasis or local tumor. She is co-Principal Investigator along with neuro-oncologist Dr. Diamond of an observational registry study of patients with Erdheim-Chester Disease (ECD) to collect baseline and follow-up clinical and patient-centered data. She also serves as the co-PI of a study to evaluate the unmet supportive care needs of patients with ECD as well as their informal caregivers. She is a member of the MSK Brain Tumor Center. She serves on the editorial board of Clin Cancer Res, JNCI and JNCI Cancer Spectrum.

Publications

  1. Kidwell KM, Postow MA, Panageas KS. Sequential, Multiple Assignment, Randomized Trial Designs in Immuno-Oncology Research. Clinical Cancer Research, 2017 Aug 23. pii: clincanres.1355.2017. doi: 10.1158/1078-0432.CCR-17-1355. [Epub ahead of print] PubMed PMID: 28835379.
  2. Goldman DA, Hovinga K, Reiner AS, Esquenazi Y, Tabar V, Panageas KS. The Relationship between Repeat Resection and Overall Survival in Glioblastoma Multiforme Patients: A Time-Dependent Analysis. J Neurosurg, in press.
  3. Eaton A., Sima CS, Panageas KS. Prevalence and safety of off-label use of chemotherapeutic agents in older breast cancer patients: estimates from SEER-Medicare data. J Natl Compr Canc Netw, 2016 Jan;14(1):57-65.
  4. Jia X, Sima CS, Brennan MB, Panageas KS. Cure Models for the Analysis of Time-to-Event Data in Cancer Studies. J Surg Oncol, 2013 Nov;108(6):342-7.
  5. Panageas KS, Ben-Porat L, Dickler MN, Chapman PB, Schrag D. When you look matters: The effect of assessment schedule on progression free survival, J Natl Can Inst. 2007; 99(6):428-32

Visit PubMed for a full listing of Katherine Panageas’ journal articles

Pubmed is an online index of biomedical articles maintained by the U.S. National Library of Medicine and the National Institutes of Health.

Disclosures

Doctors and faculty members often work with pharmaceutical, device, biotechnology, and life sciences companies, and other organizations outside of MSK, to find safe and effective cancer treatments, to improve patient care, and to educate the health care community.

MSK requires doctors and faculty members to report (“disclose”) the relationships and financial interests they have with external entities. As a commitment to transparency with our community, we make that information available to the public.

Katherine Panageas discloses the following relationships and financial interests:

  • AzurRx BioPharma
    Ownership / Equity Interests
  • Catalyst Biotech
    Ownership / Equity Interests
  • Curis
    Ownership / Equity Interests
  • Dynavax
    Ownership / Equity Interests
  • Pfizer, Inc.
    Ownership / Equity Interests
  • Sunesis Pharmaceuticals, Inc.
    Ownership / Equity Interests
  • Viking Therapeutics Inc
    Ownership / Equity Interests

The information published here is for a specific annual disclosure period. There may be differences between information on this and other public sites as a result of different reporting periods and/or the various ways relationships and financial interests are categorized by organizations that publish such data.


This page and data include information for a specific MSK annual disclosure period (January 1, 2019 through disclosure submission in spring 2020). This data reflects interests that may or may not still exist. This data is updated annually.

Learn more about MSK’s COI policies here. For questions regarding MSK’s COI-related policies and procedures, email MSK’s Compliance Office at ecoi@mskcc.org.


View all disclosures